Список литературы

Поставить закладку

Мареев В.Ю., Фомин И.В., Агеев Ф.Т., Арутюнов Г.П., Беграмбекова Ю.Л., Беленков Ю.Н. и др. Клинические рекомендации. Хроническая сердечная недостаточность (ХСН). Журнал Сердечная Недостаточность. 2017;18 (1):3–40 Doi:10.18087/rhfj.2017.1.2346.
Folsom A.R., Yamagishi K., Hozawa A. et al. Absolute and attributable risks of heart failure incidence in relation to optimal risk factors. Circ Heart Fail. 2009; 2(1): 11–17.
He J., Ogden L.G., Bazzano L.A. et al. Risk factors for congestive heart failure in US men and women: NHANES I epidemiologic follow-up study. Arch Intern Med. 2001;161(7): 996–1002.
Writing Group Members, Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, Das SR, de Ferranti S, Després JP, Fullerton HJ, Howard VJ, Huffman MD, Isasi CR, Jiménez MC, Judd SE, Kissela BM, Lichtman JH, Lisabeth LD, Liu S, Mackey RH, Magid DJ, McGuire DK, Mohler ER 3rd, Moy CS, Muntner P, Mussolino ME, Nasir K, Neumar RW, Nichol G, Palaniappan L, Pandey DK, Reeves MJ, Rodriguez CJ, Rosamond W, Sorlie PD, Stein J, Towfighi A, Turan TN, Virani SS, Woo D, Yeh RW, Turner MB; American Heart Association Statistics Committee; Stroke Statistics Subcommittee. Executive Summary: Heart Disease and Stroke Statistics--2016 Update: A Report From the American Heart Association. Circulation. 2016 Jan 26;133(4):447-54. doi: 10.1161/CIR.0000000000000366.
Roger VL, Go AS, Lloyd-Jones DM, et al. Heart disease and stroke statistics— 2011 update: a report from the American Heart Association. Circulation. 2010;123:e18–209. [PMC free article] [PubMed].
Фомин И.В., Беленков Ю.Н., Мареев В.Ю., Агеев Ф.Т., Бадин Ю.В., Галявич А.С., и др. Распространенность хронической сердечной недостаточности в Европейской части Российской Федерации – данные ЭПОХА–ХСН. Журнал Сердечная Недостаточность. 2006;7(3):112–5.
Артемьева Е.Г., Маленкова В.Ю., Фролова Е.В. Распространенность артериальной гипертензии при хронической сердечной недостаточности в Чувашской Республике. Медицинский альманах. 2011;(16):51–4.
Сергеева Е.М., Малишевский М.В., Васина А.А., Мищенко Т.А., Кузьмина Ю.С., Раемгулов Р.А. Лечение хронической сердечной недостаточности в первичном звене муниципального здравоохранения в г. Тюмени. Медицинская наука и образование Урала. 2015;16(4):32–4.
Шакирова Р.М., Галявич А.С., Камалов Г.М. Распространенность сердечно-сосудистых заболеваний и сахарного диабета в республике Татарстан и их взаимосвязь с симптомами хронической сердечной недостаточности. Журнал Сердечная Недостаточность. 2005;6(2):72–3.
Смирнова Е. А. Изучение распространенности и этиологии хронической сердечной недостаточности в Рязанской области. Российский кардиологический журнал. 2010;(2): 78– 83.
Беленков Ю. Н., Фомин И. В., Мареев В. Ю., Агеев Ф. Т., Бадин Ю. В., Галявич А. С., и др. Распространенность хронической сердечной недостаточности в Европейской части Российской Федерации данные ЭПОХА–ХСН (часть 2). Журнал Сердечная Недостаточность. 2006;7(3):3–7.
Фомин И. В. Хроническая сердечная недостаточность в Российской Федерации: что сегодня мы знаем и что должны делать. Российский кардиологический журнал. 2016;(8):7–13. DOI:10.15829/1560-4071-2016-8-7-13.
Ahmed A. Clinical manifestations, diagnostic assessment, and etiology of heart failure in older adults. Clin Geriatr Med. 2007;23:11–30. [PubMed].
Rich MW, Kitzman D. Heart failure in octogenarians: a fundamentally different disease. Am J Geriatr Cardiol 2000;9(suppl):97–104.
Sarwat I. Chaudhry, Yongfei Wang, Thomas M. Gill, Harlan M. Krumholz. Geriatric Conditions and Subsequent Mortality in Older Patients with Heart Failure. J Am Coll Cardiol. 2010 Jan 26; 55(4): 309–316. doi: 10.1016/j.jacc.2009.07.066.
Lee S, Lindquist K, Segal M, Covinsky K.: Development and validation of a prognostic index for 4-year mortality in older adults. 2006; JAMA 295:801.
Michael W. Rich, Geriatric Heart Failure: a Call for Papers, Journal of Cardiac Failure (2016), http://dx.doi.org/doi:10.1016/j.cardfail.2016.02.005.
Huffman MD, Berry JD, Ning H, et al. Lifetime risk for heart failure among white and black Americans: cardiovascular lifetime risk pooling project. J Am Coll Cardiol 2013;61(14):1510–7.
Lloyd-Jones D, Adams RJ, Brown TM, et al. Executive summary: heart disease and stroke statistics—2010 update: a report from the American Heart Association. Circulation. 2010;121:948–54. [PubMed].
Curtis LH, Whellan DJ, Hammill BG, et al. Incidence and prevalence of heart failure in elderly persons, 1994-2003. Arch Intern Med 2008;168(4):418–24
Jhund PS, Macintyre K, Simpson CR, et al. Longterm trends in first hospitalization for heart failure and subsequent survival between 1986 and 2003: a population study of 5.1 million people. Circulation 2009;119(4):515–23.
Levy D, Kenchaiah S, Larson MG, et al. Long-term trends in the incidence of and survival with heart failure. N Engl J Med 2002;347(18):1397–402
Roger VL, Weston SA, Redfield MM, et al. Trends in heart failure incidence and survival in a communitybased population. JAMA 2004;292(3):344–50
Heiat A, Gross CP, Krumholz HM. Representation of the elderly, women, and minorities in heart failure clinical trials. Arch Intern Med 2002; 162: 1682-8
Beckett N.S., Peters R., Fletcher A.E., Staessen J.A., Liu L., Dumitrascu D. et al. Treatment of hypertension in patients 80 years of age or older // N. Engl. J. Med. — 2008. — Vol. 358, № 18. — P. 1887–1898. 8.
Spargias K., Manginas A., Pavlides G. et al. Transcatheter aortic valve implantation: first Greek experience. Hellenic J Cardiol. 2008 Nov-Dec; 49 (6): 397-407.
Varadarajan P., Kapoor N., Bansal R.C., Pai R.G. Clinical profile and natural history of 453 nonsurgically managed patients with severe aortic stenosis. Ann Thorac Surg. 2006 Dec; 82 (6): 2111-5
Avery CL, Loehr LR, Baggett C, et al. The population burden of heart failure attributable to modifiable risk factors: the ARIC (Atherosclerosis Risk in Communities) study. J Am Coll Cardiol 2012;60(17):1640–6
Olivieri F, Recchioni R, Marcheselli F, Abbatecola AM, Santini G, Borghetti G, Antonicelli R, Procopio AD. Cellular senescence in cardiovascular diseases: potential age-related mechanisms and implications for treatment. Curr Pharm Des. 2013;19:1710–1719
Oxenham H, Sharpe N. Cardiovascular aging and heart failure. Eur J Heart Fail 2003;5(4):427–34
Abete P, Testa G, Della-Morte D, Gargiulo G, Galizia G, de Santis D, et al. Treatment for chronic heart failure in the elderly: current practice and problems. Heart Fail Rev 2013;18(4):529–51 doi: 10.1007/s10741-012-9363-6 [PubMed]
Dharmarajan K., Rich M.W. Epidemiology, Pathophysiology, and Prognosis of Heart Failure in Older AdultsHeart Failure Clin 13 (2017) 417–426 http://dx.doi.org/10.1016/j.hfc.2017.02.001
Altaf Pirmohamed, Dalane W Kitzman, Mathew S Maurer. Heart failure in older adults: embracing complexity. J Geriatr Cardiol 2016; 13: 8-14. doi:10.11909/j.issn.1671-5411.2016.01.020).
Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, Falk V, González-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GM, Ruilope LM, Ruschitzka F, Rutten FH van der MPAFMDR. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2016. 37:2129-200doi:10.1002/ejhf.592.
Ekundayo OJ, Howard VJ, Safford MM, et al. Value of orthopnea, paroxysmal nocturnal dyspnea, and medications in prospective population studies of incident heart failure. Am J Cardiol. 2009;104:259–64.[PMC free article] [PubMed].
Ahmed А. Chronic Heart Failure in Older Adults. Med Clin North Am. 2011 May; 95(3): 439–ix. doi:10.1016/j.mcna.2011.02.001.
Butman SM, Ewy GA, Standen JR, et al. Bedside cardiovascular examination in patients with severe chronic heart failure: importance of rest or inducible jugular venous distension. J Am Coll Cardiol. 1993;22:968–74. [PubMed].
Sochowski RA, Dubbin JD, Naqvi SZ. Clinical and hemodynamic assessment of the hepatojugular reflux. Am J Cardiol. 1990;66:1002–6. [PubMed].
Drazner MH, Rame JE, Stevenson LW, et al. Prognostic importance of elevated jugular venous pressure and a third heart sound in patients with heart failure. N Engl J Med. 2001;345:574–81. [PubMed].
Curtis JP, Selter JG, Wang Y, et al. The obesity paradox: body mass index and outcomes in patients with heart failure. Arch Intern Med. 2005;165:55–61. [PubMed]
Mueller C, Scholer A, Laule-Kilian K, et al. Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea. N Engl J Med. 2004;350:647–54. [PubMed]
Fonarow GC, Stough WG, Abraham WT, et al. Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF Registry. J Am Coll Cardiol. 2007;50:768–77. [PubMed]
Gerber Y, Weston SA, Redfield MM, et al. A contemporary appraisal of the heart failure epidemic in Olmsted County, Minnesota, 2000 to 2010. JAMA Intern Med 2015;175(6):996–1004
Owan TE, Hodge DO, Herges RM, et al. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 2006; 355(3):251–9.
Bhatia RS, Tu JV, Lee DS, et al. Outcome of heart failure with preserved ejection fraction in a populationbased study. N Engl J Med 2006;355(3):260–9
Yancy et al. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure. Circulation. 2017;000:e000–e000. DOI: 10.1161/CIR.0000000000000509
Glick D, DeFilippi CR, Christenson R, Gottdiener JS, Seliger SL. Long-term trajectory of two unique cardiac biomarkers and subsequent left ventricular structural pathology and risk of incident heart failure in community-dwelling older adults at low baseline risk. JACC Heart Fail. 2013;1:353–360. doi: 10.1016/j.jchf.2013.04.007
Roberts E, Ludman AJ, Dworzynski K, Al-Mohammad A, Cowie MR, McMurray JJV, Mant J. The diagnostic accuracy of the natriuretic peptides in heart failure: systematic review and diagnostic meta-analysis in the acute care setting. BMJ 2015;350:h910
Maisel A, Mueller C, Adams K, Jr, Anker SD, Aspromonte N, Cleland JGF, Cohen-Solal A, Dahlstrom U, DeMaria A, Di Somma S, Filippatos GS, Fonarow GC, Jourdain P, Komajda M, Liu PP, McDonagh T, McDonald K, Mebazaa A, Nieminen MS, Peacock WF, Tubaro M, Valle R, Vanderhyden M, Yancy CW, Zannad F, Braunwald E. State of the art: using natriuretic peptide levels in clinical practice. Eur J Heart Fail. 2008;10:824–839. [PubMed]
Zaphiriou A, Robb S, Murray-Thomas T, Mendez G, Fox, K, McDonagh T, Hardman SMC, Dargie HJ, Cowie MR: The diagnostic accuracy of plasma BNP and NTproBNP in patients referred from primary care with suspected heart failure: results of the UK natriuretic peptide study. Eur J Heart Fail 2005;7:537–541
Fuat A, Murphy JJ, Hungin APS, Curry J, Mehrzad AA, Hetherington A, Johnston JI, Smellie WSA, Duffy V, Cawley P. The diagnostic accuracy and utility of a B-type natriuretic peptide test in a community population of patients with suspected heart failure. Br J Gen Pract 2006;56:327–333
Yamamoto K, Burnett JC, Bermudez EA, Jougasaki M, Bailey KR, Redfield MM. Clinical criteria and biochemical markers for the detection of systolic dysfunction. J Card Fail 2000;6:194–200
Cowie MR, Struthers AD, Wood DA, Coats AJ, Thompson SG, Poole-Wilson PA, Sutton GC. Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care. Lancet 1997;350:1349–1353
Krishnaswamy P, Lubien E, Clopton P, Koon J, Kazanegra R, Wanner E, Gardetto N, Garcia A, DeMaria A, Maisel AS. Utility of B-natriuretic peptide levels in identifying patients with left ventricular systolic or diastolic dysfunction. Am J Med 2001;111:274–279.;
Kelder JC, Cramer MJ, Verweij WM, Grobbee DE, Hoes AW. Clinical utility of three B-type natriuretic peptide assays for the initial diagnostic assessment of new slow-onset heart failure. J Card Fail 2011;17:729–734.).
Maisel AS, Krishnaswamy P, Nowak RM, McCord J, Hollander JE, Duc P, Omland T, Storrow AB, Abraham WT, Wu AH, Clopton P, Steg PG, Westheim A, Knudsen CW, Perez A, Kazanegra R, Herrmann HC, McCullough PA; Breathing Not Properly Multinational Study Investigators. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med. 2002;347:161–167. doi: 10.1056/NEJMoa020233
Januzzi JL Jr, Camargo CA, Anwaruddin S, Baggish AL, Chen AA, Krauser DG, Tung R, Cameron R, Nagurney JT, Chae CU, Lloyd-Jones DM, Brown DF, Foran-Melanson S, Sluss PM, LeeLewandrowski E, Lewandrowski KB. The N-terminal Pro-BNP Investigation of Dyspnea in the Emergency Department (PRIDE) study.Am J Cardiol. 2005;95:948–954. doi: 10.1016/j.amjcard. 2004.12.032
Cynthia K. Brenden, MD,a Judd E. Hollander, MD,c David Guss, MD,d Peter A. McCullough, MD, MPH,e Richard Nowak, MD,f Gary Green, MD,g Mitchell Saltzberg, MD,h Stefanie R. Ellison, MD, FACEP,e Meenakshi Awasthi Bhalla, MD,b Vikas Bhalla, MD,b Paul Clopton, MS,b Robert Jesse, MD,i and Alan S. Maisel, MD,b for the REDHOT Investigators. Gray zone BNP levels in heart failure patients in the emergency department: Results from the Rapid Emergency Department Heart Failure Outpatient Trial (REDHOT) multicenter study. Am Heart J 2006;151:1006-11. doi:10.1016/j.ahj.2005.10.017
Sarzani R, Spannella F, Giulietti F, Fedecostante M, Giordano P, Gattafoni P, Espinosa E, Busco F, Piccinini G, Dessì-Fulgheri P. NT-proBNP and its correlation with in-hospital mortality in the very elderly without an admission diagnosis of heart failure. PLoS One. 2016 11(4):e0153759. doi: 10.1371/journal.pone.0153759
Berdague P., Caffin PY, Barazer I, Vergnes C, Sedighian S, Letrillard S, Pilossof R, Goutorbe F, Piot C, Reny JL. Use of N-terminal prohormone brain natriuretic peptide assay for etiologic diagnosis of acute dyspnea in elderly patients. Am Heart J 2006;151:690–698
Luchner A1, Behrens G, Stritzke J, Markus M, Stark K, Peters A, Meisinger C, Leitzmann M, Hense HW, Schunkert H, Heid IM. Long-term pattern of brain natriuretic peptide and N-terminal pro brain natriuretic peptide and its determinants in the general population: contribution of age, gender, and cardiac and extra-cardiac factors. Eur J Heart Fail. 2013 Aug;15(8):859-67. doi: 10.1093/eurjhf/hft048
Redfield MM., Rodehefffer RJ., Jacobsen SJ., et al. Plasma brain natriuretic peptide concentration impact of age and gender. J Am Coll Cardiol. 2002; 40: 976-982
Saif Anwaruddin, MD, Donald M. Lloyd-Jones, MD, SCM, FACC, Aaron Baggish, MD, Annabel Chen, MD, Daniel Krauser, MD, Roderick Tung, MD, Claudia Chae, MD, MPH, FACC, James L. Januzzi, JR, MD, Renal Function, Congestive Heart Failure, and Amino-Terminal Pro-Brain Natriuretic Peptide Measurement Results From the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) Study Journal of the American College of Cardiology Volume 47, Issue 1, 3 January 2006, Pages 91-97, doi:10.1016/j.jacc.2005.08.051
Sheila M. McNallan, MPH; Alanna M. Chamberlain, PhD; Yariv Gerber, PhD; Mandeep Singh, MD; Robert L. Kane, MD; Susan A. Weston, MS; Shannon M. Dunlay, MD, MSc; Ruoxiang Jiang, BS; Véronique L. Roger, MD, MPH Measuring Frailty in Heart Failure . A Community Perspective. Am Heart J. 2013;166(4):768-774
Cacciatore F, Abete P, Mazzella F, et al. Frailty predicts long-term mortality in elderly subjects with chronic heart failure. Eur J Clin Invest 2005;35:723–30
Chaudhry SI, Wang Y, Gill TM, et al. Geriatric conditions and subsequent mortality in older patients with heart failure. J Am Coll Cardiol 010;55:309–16
Lupon J, Gonzalez B, Santaeugenia S, et al. Prognostic implication of frailty and depressive symptoms in an outpatient population with heart failure. Rev Esp Cardiol 2008;61:835–42.
Newman AB, Gottdiener JS, McBurnie MA, et al. Associations of subclinical cardiovascular disease with frailty. J Gerontol A Biol Sci Med Sci 2001;56:M158–66.
Afilalo J, Karunananthan S, Eisenberg MJ, et al. Role of frailty in patients with cardiovascular disease. Am J Cardiol 2009;103:1616–21.
Fialová D, Order G. Medication errors in elderly people: contributing factors and future perspectives. Br J Clin Pharmacol. 2009;67(6):641-645.PubMedArticle.
Cudmore V, Henn P, O’Tuathaigh CMP, Smith S. Age-Related Hearing Loss and Communication Breakdown in the Clinical Setting. JAMA Otolaryngol Head Neck Surg. Published online August 24, 2017. doi:10.1001/jamaoto.2017.1248.
Wattamwar K, Qian ZJ, Otter J, et al. Increases in the rate of age-related hearing loss in the older old. JAMA Otolaryngol Head Neck Surg. 2017;143(1):41-45.PubMedArticle.
National Academies of Sciences, Engineering, and Medicine. Hearing health care for adults: Priorities for improving access and affordability. Washington, DC: The National Academies Press; 2016.
https://static1.rosminzdrav.ru/system/attachments/attaches/000/032/212/original/0 00/032/212/original/алгоритм_по_синдрому_старческой_астении.pdf?1471422279
Senn N, Monod S. Development of a Comprehensive Approach for the Early Diagnosis of Geriatric Syndromes in General Practice. Front Med (Lausanne). 2015; 2: 78.
Fried TR, McGraw S, Agostini JV, Tinetti ME. Views of older persons with multiple morbidities on competing outcomes and clinical decision-making. J Am Geriatr Soc. 2008;56:1839–1844. doi: 10.1111/j.1532-5415.2008.01923.x
ASPREE Investigator Group. Study design of ASPirin in Reducing Events in the Elderly (ASPREE): a randomized, controlled trial. Contemp Clin Trials. 2013;36:555–564
Katz S, Apkon CA. A measure of primary sociobiological functions. Int J Health Serv. 1976;6:493–507. [PubMed].
Balke B. A simple field test for the assessment of physical fitness. Rep Civ Aeromed Res Inst US. 1963(53):1 – 8.
Katz S., Down TD., Cash HR., Grotz RC. Progress in the development of the index of ADL. Gerontologist 1970, 10(1)20-30.
Lawton MP, Brody EM. Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist 1969, 9:179. Copyright 1969 Oxford University Press.
В.В. Захаров Нейропсихологические тесты. Необходимость и возможность применения. «CONSILIUM MEDICUM» ТОМ №13, № 2, с. 82-90.
Fleming КС, Evand JM, Weber DC, Chutka DS. Practical Functional Assessment of Elderly Persons: A Primary-Care Approach [Symposium on Geriatrics-Part III]. Mayo Clinic Proceedings 1995; 70:890. Copyright © 1995 Mayo Foundation.
Nordin E, Undelof N, Rosendahl E. Prognostic validity of the Timed Up-and-Go test, a modified Get-Up-and-Go test, staff's global judgement and fall history in evaluating fall risk in residential care facilities. Age Ageing 2008; 37:442. By permission of the British Geriatrics Society. Copyright 2013 Oxford University Press.
Bohannon RW. Reference Values for the Timed Up and Go Test: A Descriptive Meta-Analysis. J Geriatr Phys Ther 2006; 29:64.
Tadjibaev P, Frolova E, Gurina N, Degryse J, Vaes B. The relationship between physical performance and cardiac function in an elderly Russian cohort. Arch Gerontol Geriatr. 2014 Aug 12. pii: S0167-4943(14)00141-1. doi: 10.1016/j.archger.2014.08.003. [Epub ahead of print] [PubMed - as supplied by publisher].
Мареев В.Ю. et al., Острая декомпенсированная сердечная недостаточность. Согласованная позиция российских экспертов – 2014,” Журнал Сердечная Недостаточность, vol. 15, no. 5, pp. 321–336, 2014.
Мареев Ю.В., Герасимова В.В., Горюнова Т.В., Петрухина А.А., Даниелян М.О., Капанадзе Л.Г., Соколов С.Ф., Мареев В. Ю. Факторы, определяющие прогноз при хронической сердечной недостаточности: роль ширины и морфологии комплекса QRS. Журнал сердечная недостаточность, Т.5, с. 255–266, 2012.
Brach JS, Simonsick EM, Kritchevsky S, et al. The association between physical function and lifestyle activity and exercise in the health, aging and body composition study. J Am Geriatr Soc 2004; 52:502.
Juenger J, Schellberg D, Kraemer S, et al. Health related quality of life in patients with congestive heart failure: comparison with other chronic disease and relation to functional variables. Heart 2002; 87: 235-41.
Johnstone MJ. Quality versus quantity of life.Who should decide? Aust J Adv Nurs 1988; 6: 30-7.
Foebel AD, Liperoti R, Gambassi G, et al. Prevalence and Correlates of Cardiovascular Medication Use Among Nursing Home Residents With Ischemic Heart Disease: Results From the SHELTER Study. J Am Med Dir Assoc 2014; 15: 410-5.
Onder G, Liperoti R, Foebel A, et al. Polypharmacy and mortality among nursing home residents with advanced cognitive impairment: results from the SHELTER study. J Am Med Dir Assoc 2013; 14450.e7-12.
Forman DE, Arena R, Boxer R, Dolansky MA, Eng JJ, Fleg JL, Haykowsky M, Jahangir A, Kaminsky LA, Kitzman DW, Lewis EF, Myers J, Reeves GR, Shen WK; American Heart Association Council on Clinical Cardiology; Council on Cardiovascular and Stroke Nursing; Council on Quality of Care and Outcomes Research; and Stroke Council. Prioritizing Functional Capacity as a Principal End Point for Therapies Oriented to Older Adults With Cardiovascular Disease: A Scientific Statement for Healthcare Professionals From the American Heart Association. Circulation. 2017 Apr 18;135(16):e894-e918. doi: 10.1161/CIR.0000000000000483.
Blinderman C, Homel P, Billings A, Portenoy R, Tennstedt S. Symptom distress and quality of life in patients with advanced congestive heart failure. J Pain Symptom Manage. 2008; 35: 594-603.
Prybys K, Melville K, Hanna J, Gee A, Chyka P. Polypharmacy in the elderly: Clinical challenges in emergency practice: Part 1: Overview, etiology, and drug interactions. Emerg Med Rep. 2002;23:145–53.
Nahin RL, Fitzpatrick AL, Williamson JD, Burke GL, Dekosky ST, Furberg C GEM Study Investigators. Use of herbal medicine and other dietary supplements in community-dwelling older people: Baseline data from the ginkgo evaluation of memory study. J Am Geriatr Soc. 2006;54:1725.[PubMed]
Eisenberg DM, Kessler RC, Foster C, Norlock FE, Calkins DR, Delbanco TL. Unconventional medicine in the United States. Prevalence, costs, and patterns of use. N Engl J Med. 1993;328:246.[PubMed]
American Geriatrics Society 2015 Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults. By the American Geriatrics Society 2015 Beers Criteria Update Expert Panel Donna M. Fick, Todd P. Semla, Judith Beizer, Nicole Brandt, Robert Dombrowski, Catherine E. DuBeau, et al. J Am Geriatr Soc 63:2227–2246, 2015. https://doi.org/10.1111/jgs.13702.
Wickop B, Härterich S, Sommer C, Daubmann A, Baehr M, Langebrake C. Potentially Inappropriate Medication Use in Multimorbid Elderly Inpatients: Differences Between the FORTA, PRISCUS and STOPP Ratings. Drugs - Real World Outcomes. 2016;3(3):317-325. doi:10.1007/s40801-016-0085-2.
Gallagher P, O’Connor MN, O’Mahony D. Prevention of potentially inappropriate prescribing for elderly patients: a randomized controlled trial using STOPP/ START criteria. Clin Pharmacol Ther. 2011;89: 845– 854.
Cahir C, Bennett K, Teljeur C, Fahey T. Potentially inappropriate prescribing and adverse health outcomes in community dwelling older patients. Br J Clin Pharmacol. 2014;77:201–10.[PMC free article] [PubMed].
Mueller SK, Sponsler KC, Kripalani S, Schnipper JL. Hospital-based medication reconciliation practices: a systematic review. Arch Intern Med. 2012;172( 14): 1057– 1069.
Kanaan AO, Donovan JL, Duchin NP, et al. Adverse drug events after hospital discharge in older adults: types, severity, and involvement of Beers Criteria Medications. J Am Geriatr Soc. 2013;61( 11): 1894– 1899.
Davide Liborio Vetrano, Fabrizia Lattanzio, Anna Maria Martone, Francesco Landi, Vincenzo Brandi, Eva Topinkova and Graziano Onder. Treating Heart Failure in Older and Oldest Old Patients. Current Pharmaceutical Design, 2015, 21.
Cleland J, Tendera M, Adamus J, et al. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J 2006; 27: 2338–2345.
Little W, Wesley-Farrington D, Hoyle J, et al. Effect of candesartan and verapamil on exercise tolerance in diastolic dysfunction. J Cardiovasc Pharmacol 2004; 43: 288–293.
Groban L, Pailes N, Bennett C, et al. Growth hormone replacement attenuates diastolic dysfunction and cardiac angiotensin II expression in senescent rats. J Gerontol A Biol Sci Med Sci 2006; 61: 28–35.
Lasocki S, Iglarz M, Seince P, et al. Involvement of reninangiotensin system in pressure-flow relationship: role of angiotensin-converting enzyme gene polymorphism. Anesthesiology 2002; 96: 271–275
Yusuf S, Pfeffer M, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-preserved trial. Lancet 2003; 362: 777–781.
Heart failure with mid ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire EF spectrum. Presented at ESC Heart Failure 2017 by Lars LUND (Stockholm, Sweden) https://pace-cme.org 2017 / 04 / 30 / phenotype-hf-with-midrange-ef-resembles-hfref-albeit-with-better-outcomes.
McMurray JJ, Packer M, Desai AS, et al.: Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371(11):993–1004. 10.1056/NEJMoa1409077.
Flather MD, Shibata MC, Coats AJ, et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS) Eur Heart J. 2005;26:215–25. [PubMed].
Van Veldhuisen DJ1, Cohen-Solal A, Böhm M, Anker SD, Babalis D, Roughton M, Coats AJ, Poole-Wilson PA, Flather MD; SENIORS Investigators. Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: Data From SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Failure). Am Coll Cardiol. 2009 Jun 9;53(23):2150-8. doi: 10.1016/j.jacc.2009.02.046.
John G F Cleland, Karina V Bunting, Marcus D Flather, Douglas G Altman, Jane Holmes, Andrew J S Coats, Luis Manzano, John J V McMurray, Frank Ruschitzka, Dirk J van Veldhuisen, Thomas G von Lueder, Michael Böhm, Bert Andersson, John Kjekshus, Milton Packer, Alan S Rigby, Giuseppe Rosano, Hans Wedel, Åke Hjalmarson, John Wikstrand, Dipak Kotecha, ; Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials, European Heart Journal, Volume 39, Issue 1, 1 January 2018, Pages 26–35, https://doi.org/10.1093/eurheartj/ehx564.
Upadhya B, Taffet G, Cheng C, et al. Heart failure with preserved ejection fraction in the elderly: scope of the problem. J Mol Cell Cardiol 2015; 83: 73–87.
Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, WittesJ. The effect of spironolactone on morbidity and mortality in patients with severe heart failure: Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999; 341: 709–717.
Henry Krum, Harry Shi, Bertram Pitt, John McMurray, Karl Swedberg, Dirk J. van Veldhuisen, John Vincent, Stuart Pocock and Faiez Zannad for the EMPHASIS-HF Study Group. Clinical Benefit of Eplerenone in Patients With Mild Symptoms of Systolic Heart Failure Already Receiving Optimal Best Practice Background Drug Therapy. Circulation: Heart Failure. 2013;6:711-718, originally published July 16, 2013 https://doi.org/10.1161/CIRCHEARTFAILURE.112.000173.
Pfeffer M, Claggett B, Assmann S, et al. Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial. Circulation 2015; 131: 34–42.
Solomon SD, Claggett B, Lewis EF, et al. Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction. Eur Heart J. 2016;37(5):455-462. doi:10.1093/eurheartj/ehv464.
Kotecha D on behalf Group B in HFC. Efficacy of beta-blockers in heart failure according to left ventricular ejection fraction An individual patient level analysis of double-blind randomised trials. ESC 2017. 2017.
Lund LH on behalf of the CSG. Heart failure with mid ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire EF spectrum. HFA 2017. 2017.
Ahmed A. Digoxin and reduction in mortality and hospitalization in geriatric heart failure: importance of low doses and low serum concentrations. J Gerontol A Biol Sci Med Sci. 2007;62:323–9.
Ahmed A, Rich MW, Fleg JL, et al. Effects of digoxin on morbidity and mortality in diastolic heart failure: the ancillary digitalis investigation group trial. Circulation. 2006;114:397–403.
Ahmed A, Rich MW, Love TE, et al. Digoxin and reduction in mortality and hospitalization in heart failure: a comprehensive post hoc analysis of the DIG trial. Eur Heart J. 2006;27:178–86.
Lalia AZ, Dasari S, Robinson MM, et al. Influence of omega-3 fatty acids on skeletal muscle protein metabolism and mitochondrial bioenergetics in older adults. Aging (Albany NY). 2017;9(4):1096-1115. doi:10.18632/aging.101210.
Tsimploulis A, Lam PH, Arundel C, et al. Systolic Blood Pressure and Outcomes in Patients With Heart Failure With Preserved Ejection Fraction. JAMA Cardiol. Published online February 14, 2018. doi:10.1001/jamacardio.2017.5365.
Ferreira JP, Duarte K, Pfeffer MA, McMurray JJV, Pitt B, Dickstein K, Zannad F, Rossignol P; High-Risk Myocardial Infarction Database Initiative.Association between mean systolic and diastolic blood pressure throughout the follow-up and cardiovascular events in acute myocardial infarction patients with systolic dysfunction and/or heart failure: an analysis from the High-Risk Myocardial Infarction Database Initiative. Eur J Heart Fail. 2018 Jan 4. doi: 10.1002/ejhf.1131.
Ревишвили А.Ш. et al., Клинические рекомендации по проведению электрофизиологических исследований, катетерной абляции и применению имплантируемых антиаритмических устройств, 2017. [Online]. Available: https://vnoa.ru/upload/Recomendation_2017_30_10_2017_HR.pdf.
. MAREEV V.Y et al., Clinical guidelines. Chronic heart failure (CHF), Russ. Hear. Fail. J., vol. 18, no. 1, pp. 3–40, 2017.
C. W. WRITING COMMITTEE MEMBERS et al., 2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America., Circulation, vol. 134, no. 13, pp. e282-93, Sep. 2016.
Ponikowski P. et al., 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution o, Eur. Heart J., vol. 37, no. 27, pp. 2129–2200, Jul. 2016.
Leon M.B. et al., Transcatheter Aortic-Valve Implantation for Aortic Stenosis in Patients Who Cannot Undergo Surgery, N. Engl. J. Med., vol. 363, no. 17, pp. 1597–1607, Oct. 2010.
Nielsen J.C. et al., A comparison of single-lead atrial pacing with dual-chamber pacing in sick sinus syndrome, Eur. Heart J., vol. 32, no. 6, pp. 686–696, Mar. 2011.
Lamas G.A. et al., Ventricular Pacing or Dual-Chamber Pacing for Sinus-Node Dysfunction, N. Engl. J. Med., vol. 346, no. 24, pp. 1854–1862, Jun. 2002.
Andersen H.R., Thuesen L., Bagger J.P., Vesterlund T., and Thomsen P.E., Prospective randomised trial of atrial versus ventricular pacing in sick-sinus syndrome., Lancet (London, England), vol. 344, no. 8936, pp. 1523–8, Dec. 1994.
Heldman D.et al., True incidence of pacemaker syndrome., Pacing Clin. Electrophysiol., vol. 13, no. 12 Pt 2, pp. 1742–50, Dec. 1990.
Wilkoff B.L. et al., The DAVID (Dual Chamber and VVI Implantable Defibrillator) II trial., J. Am. Coll. Cardiol., vol. 53, no. 10, pp. 872–80, Mar. 2009.
M. D. for the C. R. — H. F. (CARE-H. S. I. John G.F. Cleland, M.D., Jean-Claude Daubert, M.D., Erland Erdmann, M.D., Nick Freemantle, Ph.D., Daniel Gras, M.D., Lukas Kappenberger, M.D., and Luigi Tavazzi, The Effect of Cardiac Resynchronization on Morbidity and Mortality in Heart Failure — NEJM, N Engl J Med 2005; 352:1539-1549, 2005. http://www.nejm.org/doi/full/10.1056/NEJMoa050496.
A. S. L. Tang et al., Cardiac-resynchronization therapy for mild-to-moderate heart failure, N. Engl. J. Med., vol. 363, no. 25, pp. 2385–95, Dec. 2010.
P. Santangeli et al., Meta-analysis: age and effectiveness of prophylactic implantable cardioverter-defibrillators., Ann. Intern. Med., vol. 153, no. 9, pp. 592–9, Nov. 2010.
Steinberg B.A. et al., Outcomes of implantable cardioverter-defibrillator use in patients with comorbidities: Results from a combined analysis of 4 randomized clinical trials, JACC Hear. Fail., vol. 2, no. 6, pp. 623–629, 2014.
Kober L. et al., “Defibrillator Implantation in Patients with Nonischemic Systolic Heart Failure,” N. Engl. J. Med., p. NEJMoa1608029, Aug. 2016.
TIME Investigators, “Trial of invasive versus medical therapy in elderly patients with chronic symptomatic coronary-artery disease (TIME): a randomised trial,” Lancet, vol. 358, no. 9286, pp. 951–957, Sep. 2001.
M. Pfisterer and Trial of Invasive versus Medical therapy in Elderly patients Investigators, “Long-Term Outcome in Elderly Patients With Chronic Angina Managed Invasively Versus by Optimized Medical Therapy: Four-Year Follow-Up of the Randomized Trial of Invasive Versus Medical Therapy in Elderly Patients (TIME),” Circulation, vol. 110, no. 10, pp. 1213–1218, Sep. 2004.
Wenger N.K., Helmy T., Patel A.D., and Lerakis S., “Evidence-based management of coronary artery disease in the elderly--current perspectives.,” MedGenMed, vol. 7, no. 2, p. 75, Apr. 2005.
Petrie M.C. et al., “Ten-Year Outcomes After Coronary Artery Bypass Grafting According to Age in Patients With Heart Failure and Left Ventricular Systolic DysfunctionClinical Perspective,” Circulation, vol. 134, no. 18, pp. 1314–1324, Nov. 2016.
Baumgartner H. et al., “2017 ESC/EACTS Guidelines for the management of valvular heart disease,” Eur. Heart J., vol. 38, no. 36, pp. 2739–2791, Aug. 2017.
Арутюнов Г.П., Колесникова Е.А., Беграмбекова Ю.Л., Орлова Я.А., Рылова А.К., Аронов Д.М., Агеев Ф.Т., Беленков Ю.Н., Бубнова М.Г., Васюк Ю.А., Галявич А.С., Гарганеева А.А., Гендлин Г.Е., Гиляревский С.Р., Глезер М.Г., Драпкина О.М., Дупляков Д.В., Кобалава Ж.Д., Козиолова Н.А., Лопатин Ю.М., Мареев В.Ю., Мустаева С.Э., Перепеч Н.Б., Полтавская М.Г., Свет А.В., Середенина Е.М., Ситникова М.Ю., Скибицкий В.В., Тарловская Е.И., Фомин И.В., Чесникова А.И., Шляхто Е.В. Рекомендации по назначению физических тренировок пациентам с хронической сердечной недостаточностью. Сердечная недостаточность, 18(1.):41– 66, 2017.
Iolascon G., Di Pietro G., Gimigliano F. et al. Physical exercise and sarcopenia in older people: position paper of the Italian Society of Orthopaedics and Medicine (OrtoMed) // Clinical Cases in Mineral and Bone Metabolism. 2014. Vol. 11, N 3. P. 215– 221
Орлова Я. А. Особенности физической реабилитации пожилых пациентов с ХСН // Сердечная недостаточность. — 2016. — Т. 17, № 6. — С. 365–375. [ DOI ]]
McMurray JJ. Improving outcomes in heart failure: a personal perspective. Eur Heart J 2015; 36: 3467–3470 http://dx.doi.org/10.1093/eurheartj/ehv565
Brüllmann S, Dichtl W, Paoli U, et al. Comparison of benefit and mortality of implantable cardioverter-defibrillator therapy in patients aged >75 years versus those <75 years. Am J Cardiol 2012; 109: 712-7
Dev S, Abernethy AP, Rogers JG, O'Connor CM. Preferences of people with advanced heart failure-a structured narrative literature review to inform decision making in the palliative care setting. Am Heart J 2012; 164: 313-9
McKelvie RS, Moe GW, Cheung A, et al. The 2011 Canadian Cardiovascular Society heart failure management guidelines update: focus on sleep apnea, renal dysfunction, mechanical circulatory support, and palliative care. Can J Cardiol 2011; 27: 319-38
Rogers JG, Patel CB, Mentz RJ, Granger BB, Steinhauser KE, Fiuzat M, Adams PA, Speck A, Johnson KS, Krishnamoorthy A, Yang H, Anstrom KJ, Dodson GC, Taylor DH Jr, Kirchner JL, Mark DB, O'Connor CM, Tulsky JA Palliative Care in Heart Failure: The PAL-HF Randomized, Controlled Clinical Trial. J Am Coll Cardiol. 2017 Jul 18;70(3):331-341. doi: 10.1016/j.jacc.2017.05.030.
Lindvall C, Hultman TD, Jackson VA. Overcoming the barriers to palliative care referral for patients with advanced heart failure. J Am Heart Assoc. 2014 Feb;3(1):e000742
Walke LM, Gallo WT, Tinetti ME, Fried TR. The burden of symptoms among community-dwelling older persons with advanced chronic disease. Arch Intern Med. 2004;164(21):2321
Bekelman DB, Nowels CT, Allen LA, Shakar S, Kutner JS, Matlock DD. Outpatient palliative care for chronic heart failure: a case series. J Palliat Med. 2011 Jul;14(7):815-21
Heo S, Doering LV, Widener J, Moser DK. Predictors and effect of physical symptom status on health-related quality of life in patients with heart failure. Am J Crit Care. 2008 Mar;17(2):124-32
Bekelman DB, Rumsfeld JS, Havranek EP, Yamashita TE, Hutt E, Gottlieb SH, Dy SM, Kutner JS. Symptom burden, depression, and spiritual well-being: a comparison of heart failure and advanced cancer patients. J Gen Intern Med. 2009;24(5):592
Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, Fonarow GC, Geraci SA, Horwich T, Januzzi JL, Johnson MR, Kasper EK, Levy WC, Masoudi FA, McBride PE, McMurray JJ, Mitchell JE, Peterson PN, Riegel B, Sam F, Stevenson LW, Tang WH, Tsai EJ, Wilkoff BL. 2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2013;128(16):1810
Reinke LF, Slatore CG, Uman J, Udris EM, Moss BR, Engelberg RA, Au DH Patient-clinician communication about end-of-life care topics: is anyone talking to patients with chronic obstructive pulmonary disease? J Palliat Med. 2011 Aug;14(8):923-8
Williams SG, Wright DJ, Marshall P, Reese A, Tzeng BH, Coats AJ, Tan LB. Safety and potential benefits of low dose diamorphine during exercise in patients with chronic heart failure. Heart. 2003;89(9):1085
Chua TP, Harrington D, Ponikowski P, Webb-Peploe K, Poole-Wilson PA, Coats AJ. Effects of dihydrocodeine on chemosensitivity and exercise tolerance in patients with chronic heart failure. J Am Coll Cardiol. 1997;29(1):147
Johnson MJ, McDonagh TA, Harkness A, McKay SE, Dargie HJ. Morphine for the relief of breathlessness in patients with chronic heart failure--a pilot study. Eur J Heart Fail. 2002;4(6):753
Ekström M, Nilsson F, Abernethy AA, Currow DC . Effects of opioids on breathlessness and exercise capacity in chronic obstructive pulmonary disease. A systematic review. Ann Am Thorac Soc. 2015;12(7):1079).
Ekström MP, Bornefalk-Hermansson A, Abernethy AP, Currow DC. Safety of benzodiazepines and opioids in very severe respiratory disease: national prospective study. BMJ. 2014;348:g445
Bradley TD, Logan AG, Kimoff RJ, Sériès F, Morrison D, Ferguson K, Belenkie I, Pfeifer M, Fleetham J, Hanly P, Smilovitch M, Tomlinson G, Floras JS, CANPAP Investigators. Continuous positive airway pressure for central sleep apnea and heart failure. N Engl J Med. 2005;353(19):2025
Beniaminovitz A, Lang CC, LaManca J, Mancini DM. Selective low-level leg muscle training alleviates dyspnea in patients with heart failure. J Am Coll Cardiol. 2002;40(9):1602).
Gysels MH, Higginson IJ. Caring for a person in advanced illness and suffering from breathlessness at home: threats and resources. Palliat Support Care. 2009 Jun;7(2):153-62
Evangelista LS, Moser DK, Westlake C, Pike N, Ter-Galstanyan A, Dracup K. Correlates of fatigue in patients with heart failure. Prog Cardiovasc Nurs. 2008;23(1):12
Quittan M, Wiesinger GF, Sturm B, Puig S, Mayr W, Sochor A, Paternostro T, Resch KL, Pacher R, Fialka-Moser V. Improvement of thigh muscles by neuromuscular electrical stimulation in patients with refractory heart failure: a single-blind, randomized, controlled trial. Am J Phys Med Rehabil. 2001 Mar;80(3):206-14; quiz 215-6, 224
Goodlin SJ, Wingate S, Albert NM, Pressler SJ, Houser J, Kwon J, Chiong J, Storey CP, Quill T, Teerlink JR, PAIN-HF Investigators. Investigating pain in heart failure patients: the pain assessment, incidence, and nature in heart failure (PAIN-HF) study. J Card Fail. 2012 Oct;18(10):776-83).
ArfeA, Scotti L, Varas-Lorenzo C, Nicotra F, Zambon A, Kollhorst B, Schink T, Garbe E, Herings R, Straatman H, Schade R, Villa M, Lucchi S, Valkhoff V, Romio S, Thiessard F, Schuemie M, Pariente A, Sturkenboom M, Corrao G, Safety of Non-steroidal Anti-inflammatory Drugs (SOS) Project Consortium. Non-steroidal anti-inflammatory drugs and risk of heart failure in four European countries: nested case-control study. BMJ. 2016 Sep;354:i4857
Zis P, Daskalaki A, Bountouni I, Sykioti P, Varrassi G, Paladini A. Depression and chronic pain in the elderly: links and management challenges. Clinical Interventions in Aging. 2017;12:709-720. doi:10.2147/CIA.S113576.
De Smedt RH, Denig P, Haaijer-Ruskamp FM, Jaarsma T. Perceived medication adverse effects and coping strategies reported by chronic heart failure patients. Int J Clin Pract. 2009 Feb;63(2):233-42
Sullivan M, Levy WC, Russo JE, Spertus JA. Depression and health status in patients with advanced heart failure: a prospective study in tertiary care. J Card Fail. 2004;10(5):390
Gottlieb SS, Kop WJ, Thomas SA, Katzen S, Vesely MR, Greenberg N, Marshall J, Cines M, Minshall S. A double-blind placebo-controlled pilot study of controlled-release paroxetine on depression and quality of life in chronic heart failure. Am Heart J. 2007;153(5):868).
O'Connor CM, Jiang W, Kuchibhatla M, Silva SG, Cuffe MS, Callwood DD, Zakhary B, Stough WG, Arias RM, Rivelli SK, Krishnan R, SADHART-CHF Investigators. Safety and efficacy of sertraline for depression in patients with heart failure: results of the SADHART-CHF (Sertraline Against Depression and Heart Disease in Chronic Heart Failure) trial. J Am Coll Cardiol. 2010;56(9):692
Bekelman DB, Sullivan M. Depression and Anxiety in Patients with Chronic Heart Failure. In: Supportive Care in Heart Failure, Beattie J, Goodlin SJ (Eds), Oxford University Press, 2008.80
Kirby D, Ames D. Hyponatraemia and selective serotonin re-uptake inhibitors in elderly patients. Int J Geriatr Psychiatry. 2001;16(5):484).
Glassman AH. Cardiovascular Effects of Tricyclic Antidepressants. Annual Review of Medicine. 1984;35(1):503–11. DOI:10.1146/annurev.me.35.020184.002443
Goldberg RJ, Capone RJ, Hunt JD. Cardiac complications following tricyclic antidepressant overdose. Issues for monitoring policy. JAMA. 1985;254(13):1772–5
Pacher P, Ungvari Z, Nanasi PP, Furst S, Kecskemeti V. Speculations on difference between tricyclic and selective serotonin reuptake inhibitor antidepressants on their cardiac effects. Is there any? Curr Med Chem. 1999;6(6):469–80
Burris KD, Molski TF, Xu C, Ryan E, Tottori K, Kikuchi T, и др. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther. 2002;302(1):381–9
Jordan S, Koprivica V, Chen R, Tottori K, Kikuchi T, Altar CA. The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor. Eur J Pharmacol. 2002;441(3):137–40
Mahoney FI, Barthel DW. Functional evaluation: the barthel index.Md State Med J. 1965 :61-5